ClearPoint Neuro (CLPT) Gets FDA's Nod for New Software

ClearPoint Neuro, Inc. (CLPT) recently announced its receipt of the FDA’s clearance and first-in-human cases using the ClearPoint 2.2 Software with integrated Maestro Brain Modeling. The company also announced the publication of a key validation study for its ClearPoint Maestro Brain Model in the peer-reviewed journal NeuroImage.The first clinical cases using ClearPoint 2.2 were completed successfully in the current quarter. The company expects a full market release in the second half of 2024.The latest reg ...